 |
PDBsum entry 4rlt
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Lyase/lyase inhibitor
|
PDB id
|
|
|
|
4rlt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Molecular basis for the inhibition of β-Hydroxyacyl-Acp dehydratase hadab complex from mycobacterium tuberculosis by flavonoid inhibitors.
|
 |
|
Authors
|
 |
Y.Dong,
X.Qiu,
N.Shaw,
Y.Xu,
Y.Sun,
X.Li,
J.Li,
Z.Rao.
|
 |
|
Ref.
|
 |
Protein Cell, 2015,
6,
504-517.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Dehydration is one of the key steps in the biosynthesis of mycolic acids and is
vital to the growth of Mycobacterium tuberculosis (Mtb). Consequently, stalling
dehydration cures tuberculosis (TB). Clinically used anti-TB drugs like
thiacetazone (TAC) and isoxyl (ISO) as well as flavonoids inhibit the enzyme
activity of the β-hydroxyacyl-ACP dehydratase HadAB complex. How this
inhibition is exerted, has remained an enigma for years. Here, we describe the
first crystal structures of the MtbHadAB complex bound with flavonoid inhibitor
butein, 2',4,4'-trihydroxychalcone or fisetin. Despite sharing no sequence
identity from Blast, HadA and HadB adopt a very similar hotdog fold. HadA forms
a tight dimer with HadB in which the proteins are sitting side-by-side, but are
oriented anti-parallel. While HadB contributes the catalytically critical
His-Asp dyad, HadA binds the fatty acid substrate in a long channel. The
atypical double hotdog fold with a single active site formed by MtbHadAB gives
rise to a long, narrow cavity that vertically traverses the fatty acid binding
channel. At the base of this cavity lies Cys61, which upon mutation to Ser
confers drug-resistance in TB patients. We show that inhibitors bind in this
cavity and protrude into the substrate binding channel. Thus, inhibitors of
MtbHadAB exert their effect by occluding substrate from the active site. The
unveiling of this mechanism of inhibition paves the way for accelerating
development of next generation of anti-TB drugs.
|
 |
|
|
|
|
 |